LAUSR

Hovelmann et al. [1] have diligently examined the pharmacokinetics of a fast-acting insulin formulation (Aspart) in healthy human volunteers following subcutaneous (SC) administration to three different sites, namely: abdomen, upper arm and thigh [1]. From a pharmacokinetic perspective, it appeared that abdomen and upper arm produced relatively higher exposure of insulin at early time points; however, it was recommended that Aspart could be administered at any SC injection site suggesting that from a pharmacodynamic perspective all injection sites of Aspart dose would have behaved similarly. Although the focus of the investigation was to determine pharmacokinetics of Aspart, such supportive data for the three injection sites were gathered from a previous pharmacodynamic study of fast-acting Aspart [2].